25,000 Shares in Artivion, Inc. $AORT Bought by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. acquired a new stake in shares of Artivion, Inc. (NYSE:AORT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,000 shares of the company’s stock, valued at approximately $562,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AORT. Royal Bank of Canada grew its holdings in shares of Artivion by 73.1% in the first quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock valued at $3,430,000 after acquiring an additional 39,553 shares in the last quarter. Vanguard Group Inc. boosted its position in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Orbimed Advisors LLC bought a new position in Artivion in the 1st quarter valued at $5,530,000. UBS Group AG grew its stake in Artivion by 37.0% in the 4th quarter. UBS Group AG now owns 279,675 shares of the company’s stock valued at $12,756,000 after purchasing an additional 75,606 shares during the period. Finally, Fifth Third Bancorp increased its position in shares of Artivion by 58,029.7% during the 1st quarter. Fifth Third Bancorp now owns 123,235 shares of the company’s stock valued at $4,513,000 after purchasing an additional 123,023 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Artivion Trading Up 0.6%

Artivion stock opened at $28.16 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The stock has a market cap of $1.37 billion, a P/E ratio of -402.23 and a beta of 1.25. The firm’s fifty day moving average price is $25.08 and its 200-day moving average price is $30.14.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Equities research analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AORT. Weiss Ratings downgraded shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Citigroup restated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Canaccord Genuity Group lifted their price target on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Finally, Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

Insiders Place Their Bets

In related news, CEO James P. Mackin sold 70,000 shares of Artivion stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the transaction, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This trade represents a 7.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of Artivion stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the transaction, the senior vice president owned 184,118 shares in the company, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 114,978 shares of company stock valued at $2,965,155. 6.30% of the stock is currently owned by corporate insiders.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.